Background: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Patients and methods: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. Conclusions: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.
Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma : a phase II trial of 22 patients / L. Licitra, R. Cavina, C. Grandi, S. Di Palma, M. Guzzo, R. Demicheli, R. Molinari. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 7:6(1996 Aug), pp. 640-642. [10.1093/oxfordjournals.annonc.a010684]
Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma : a phase II trial of 22 patients
L. Licitra;
1996
Abstract
Background: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Patients and methods: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. Conclusions: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.File | Dimensione | Formato | |
---|---|---|---|
pmid 8879381.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
192.54 kB
Formato
Adobe PDF
|
192.54 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.